Sandoz Group AG is a Swiss company specializing in generic pharmaceuticals and biosimilars. It serves as the global leader in providing affordable generic and biosimilar medicines, with a purpose centered on pioneering access to treatments for patients worldwide. The company develops, manufactures, and commercializes a broad portfolio of off-patent medicines, including complex generics and high-value biosimilars that offer cost-effective alternatives to biologic therapies. Sandoz Group AG operates in key therapeutic areas such as oncology, immunology, endocrinology, and cardiovascular health, addressing critical needs in both developed and emerging markets. Its B2B business unit supplies active pharmaceutical ingredients, out-licenses finished dosage forms, and provides contract manufacturing services. Headquartered in Basel, Switzerland, with major operations in Holzkirchen, Germany; Prague, Czechia; Barcelona, Spain; and Kufstein, Austria, Sandoz Group AG plays a vital role in the healthcare sector by enhancing medicine affordability and availability through its extensive global footprint.